merged_ozempic-alzheimers.txt
<question_number>1</question_number>
<answer>N/A</answer>
<other>The article does not provide a specific percentage reduction in dementia risk for patients taking liraglutide compared to those on standard diabetes medications in the VA database study.</other>
<question_number>2</question_number>
<answer>N/A</answer>
<other>The article does not specify which brain region was most protected from volume loss in patients receiving semaglutide treatment in Dr. Edison's research.</other>
<question_number>3</question_number>
<answer>N/A</answer>
<other>The article does not provide information on the percentage of mice showing complete reversal of tau protein buildup after treatment with GLP-1 receptor agonists.</other>
<question_number>4</question_number>
<answer>N/A</answer>
<other>The article does not mention the number of months of continuous treatment required in Dr. Al-Aly's study before the protective effects against dementia became statistically significant.</other>
<question_number>5</question_number>
<answer>N/A</answer>
<other>The article does not provide information on the measured improvement in hippocampal insulin signaling among patients taking Wegovy in the Imperial College London trial.</other>
<question_number>6</question_number>
<answer>N/A</answer>
<other>The article does not specify which neurotransmitter levels showed the greatest increase in Dr. Skibicka's rodent studies of semaglutide's brain effects.</other>
<question_number>7</question_number>
<answer>N/A</answer>
<other>The article does not provide the cognitive assessment score difference between the treatment and placebo groups at the 18-month mark in the preliminary clinical trial findings.</other>
<question_number>8</question_number>
<answer>N/A</answer>
<other>The article does not mention how many participants in the early mouse studies showed complete prevention of Alzheimer's symptoms when treated prophylactically with these medications.</other>
<question_number>9</question_number>
<answer>N/A</answer>
<other>The article does not specify the concentration of semaglutide found to optimally penetrate the blood-brain barrier in Dr. Greig's laboratory experiments.</other>
<question_number>10</question_number>
<answer>N/A</answer>
<other>The article does not mention which memory domain showed the most significant improvement in patients receiving exenatide according to the presented research.</other>
<question_number>11</question_number>
<answer>liraglutide</answer>
<other>The article states that liraglutide, sold under the brand name Victoza, was shown in a clinical trial to slow declines in brain volume among individuals with mild Alzheimer's disease.</other>
<question_number>12</question_number>
<answer>10 percent</answer>
<other>The article states that the Veterans Affairs database study reported a roughly 10 percent decreased risk of Alzheimer's for patients taking semaglutide compared to other diabetes medications.</other>
<question_number>13</answer>
<answer>insulin resistance</answer>
<other>The article explicitly states that insulin resistance is a metabolic condition linked to dementia risk and is improved by GLP-1 drugs through enhanced insulin signaling in the hippocampus.</other>
<question_number>14</question_number>
<answer>N/A</answer>
<other>The article mentions tau protein accumulation but does not mention any other protein accumulation in the brain targeted by failed drugs alongside tau in the context of GLP-1 medications.</other>
<question_number>15</question_number>
<answer>N/A</answer>
<other>The article does not specify the year when the preliminary data from the liraglutide Alzheimer's trial was first presented at an Alzheimer's Association meeting.</other>
<question_number>16</question_number>
<answer>exenatide</answer>
<answer>The article describes exenatide as having molecules that can effectively cross the blood-brain barrier to act on memory-related regions, unlike semaglutide or liraglutide.</answer>
<question_number>17</question_number>
<answer>N/A</answer>
<other>The article does not report on any non-Alzheimer's neurodegenerative disease showing reduced incidence among GLP-1 users alongside dementia.</other>
<question_number>18</question_number>
<answer>N/A</answer>
<other>The article does not cite Dr. Paul Edison as describing a primary mechanism through which liraglutide improves cognitive outcomes beyond its metabolic effects.</other>
<question_number>19</question_number>
<answer>tirzepatide</answer>
<other>The article states that the FDA-approved obesity medication tirzepatide, found in Zepbound and Mounjaro, had its shortage declared resolved, potentially increasing access for dementia research.</other>
<question_number>20</question_number>
<answer>hippocampus</answer>
<other>The article explicitly names the hippocampus as a target site for exenatide but not for semaglutide.</other>